RxSight (RXST) Expected to Announce Quarterly Earnings on Wednesday

RxSight (NASDAQ:RXST) is anticipated to issue its Q4 2025 results after the market closes on Wednesday, February 25th. Analysts expect the company to announce earnings of ($0.25) per share and revenue of $32.6020 million for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 4:30 PM ET.

RxSight Stock Performance

Shares of RXST stock opened at $8.85 on Tuesday. The stock has a market cap of $363.91 million, a PE ratio of -10.06 and a beta of 1.14. The business’s fifty day moving average is $9.68 and its 200-day moving average is $9.48. RxSight has a 1 year low of $6.32 and a 1 year high of $29.78.

Hedge Funds Weigh In On RxSight

Several hedge funds and other institutional investors have recently added to or reduced their stakes in RXST. Raymond James Financial Inc. acquired a new position in RxSight during the second quarter worth $28,000. Caitong International Asset Management Co. Ltd raised its stake in shares of RxSight by 440.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,758 shares of the company’s stock valued at $39,000 after acquiring an additional 3,063 shares in the last quarter. Larson Financial Group LLC lifted its holdings in RxSight by 110.5% in the 3rd quarter. Larson Financial Group LLC now owns 3,979 shares of the company’s stock worth $36,000 after purchasing an additional 2,089 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in RxSight by 156.2% during the second quarter. Tower Research Capital LLC TRC now owns 5,574 shares of the company’s stock worth $72,000 after purchasing an additional 3,398 shares during the period. Finally, Russell Investments Group Ltd. boosted its position in RxSight by 112.3% during the second quarter. Russell Investments Group Ltd. now owns 8,684 shares of the company’s stock worth $113,000 after purchasing an additional 4,593 shares during the period. Institutional investors own 78.78% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on RXST shares. Wolfe Research upgraded RxSight to an “outperform” rating in a report on Friday, January 30th. Piper Sandler raised their target price on shares of RxSight from $10.00 to $11.00 and gave the stock a “neutral” rating in a report on Tuesday, January 20th. JPMorgan Chase & Co. lifted their target price on shares of RxSight from $8.00 to $9.00 and gave the stock an “underweight” rating in a research report on Thursday, November 6th. Morgan Stanley boosted their price target on shares of RxSight from $9.00 to $10.00 and gave the company an “equal weight” rating in a report on Tuesday, December 2nd. Finally, Needham & Company LLC raised their price objective on shares of RxSight from $11.00 to $12.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Two investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, RxSight presently has a consensus rating of “Reduce” and a consensus price target of $9.78.

RxSight Company Profile

RxSight, Inc is a medical technology company focused on the development and commercialization of advanced intraocular lens (IOL) systems for patients undergoing cataract surgery and lens replacement procedures. The company’s flagship product, the Light Adjustable Lens (LAL), is designed to provide customized vision correction by allowing non‐invasive post‐operative adjustments. Using ultraviolet light, surgeons can fine‐tune the lens power after implantation to achieve optimal visual outcomes, reducing reliance on glasses or contact lenses and enhancing patient satisfaction.

Founded in 2011 and headquartered in Aliso Viejo, California, RxSight has pursued regulatory clearances and market access across multiple regions.